Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 28.1
edited by manuelmenendez
on 2025/01/29 18:50
on 2025/01/29 18:50
Change comment:
There is no comment for this version
To version 22.1
edited by manuelmenendez
on 2025/01/29 18:44
on 2025/01/29 18:44
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for CNSdiseases// =5 += //A new tridimensional diagnostic framework for neurodegenerative diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNSdiseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.7 +This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) ... ... @@ -15,16 +15,17 @@ 15 15 ((( 16 16 = What is this about and what can I find here? = 17 17 18 -= **Overview** = 18 +== **Overview** == 19 19 20 -The classification anddiagnosisof centralnervous system (CNS) diseases have longbeenconstrained by traditional phenotypicapproaches that fail to capture the underlying pathophysiologicalmechanisms, molecularbiomarkers, andneuroanatomical changesthat drive disease progression.Asneurodegenerativeandpsychiatric disorders exhibit significant clinical overlap, co-pathology, and heterogeneity, a new diagnostic framework isurgentlyneeded—one that shifts from symptom-basedclassifications toward anetiology-driven,tridimensional systemintegrating genetics, proteomics, neuroimaging, and computational modeling. By leveraging AI, multi-modal biomarkers, and precision medicine, thisframework aims to provide a more objective, scalable, and biologically grounded approach to diagnosingand managing CNS diseases, ultimately leading toearlier detection, personalized interventions, and improved patient outcomes.20 +The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on: 21 21 22 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 23 - 24 24 * **Axis 1**: Etiology (genetic or other causes of diseases). 25 25 * **Axis 2**: Molecular Markers (biomarkers). 26 26 * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 27 27 26 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 27 + 28 + 28 28 This methodology enables: 29 29 30 30 * Greater precision in diagnosis. ... ... @@ -31,18 +31,14 @@ 31 31 * Integration of incomplete datasets using AI-driven probabilistic modeling. 32 32 * Stratification of patients for personalized treatment. 33 33 34 -== ** The case of neurodegenerativediseases** ==35 +== **Diagnostic Axes** == 35 35 36 -There have been described these 3 diagnostic axes: 37 - 38 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 39 - 40 40 * ((( 41 41 **Axis 1: Etiology** 42 42 43 43 * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 44 44 * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 45 -* //Tests//: Genetic testing, lifestyle ,and cardiovascular screening.42 +* //Tests//: Genetic testing, lifestyle and cardiovascular screening. 46 46 ))) 47 47 * ((( 48 48 **Axis 2: Molecular Markers** ... ... @@ -84,9 +84,6 @@ 84 84 ))) 85 85 86 86 87 - 88 - 89 - 90 90 (% class="col-xs-12 col-sm-4" %) 91 91 ((( 92 92 {{box title="**Contents**"}}